{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:20:32Z","timestamp":1783696832524,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["ACR Open Rheumatology"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate the impact of baseline and time\u2010varying factors on the risk of serious adverse events (SAEs) in patients during long\u2010term certolizumab pegol (CZP) treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA), and plaque psoriasis (PSO). Cox proportional hazards modeling was used to investigate the association of baseline patient characteristics with risk of serious infectious events (SIEs), malignancies, and major adverse cardiac events (MACEs). Cox modeling for recurrent events assessed the impact of time\u2010varying body mass index (BMI), systemic corticosteroid (CS) use, and disease activity on SIE risk in RA and SAE risk in PSO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data were pooled from 8747 CZP\u2010treated patients across indications. Cox models reported a 44% increase in SIE risk associated with a baseline BMI of 35 kg\/m<jats:sup>2<\/jats:sup> or more versus a baseline BMI of 18.5 kg\/m<jats:sup>2<\/jats:sup> to less than 25 kg\/m<jats:sup>2<\/jats:sup>. Baseline systemic CS use, age of 65 years or more, and disease duration of 10 years or longer also increased SIE risk. Older age was the only identified risk factor for malignancies. The risk of MACEs increased 107% for BMI of 35 kg\/m<jats:sup>2<\/jats:sup> or more versus BMI of 18.5 kg\/m<jats:sup>2<\/jats:sup> to less than 25 kg\/m<jats:sup>2<\/jats:sup> and increased 51% for men versus women. Higher disease activity, older age, systemic CS use, BMI of 35 kg\/m<jats:sup>2<\/jats:sup> or more, and baseline comorbidities were SIE risk factors in RA. Age and systemic CS use were risk factors for SAEs in PSO.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Age, BMI, systemic CS use, and disease activity were identified as SIE risk factors in CZP\u2010treated patients. Risk of malignancies was greater in older patients, whereas obesity and male sex were MACE risk factors.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr2.11259","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T02:01:56Z","timestamp":1625191316000},"page":"501-511","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index"],"prefix":"10.1002","volume":"3","author":[{"given":"Vivian P.","family":"Bykerk","sequence":"first","affiliation":[{"name":"Hospital for Special Surgery New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Curtis","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Gaujoux\u2010Viala","sequence":"additional","affiliation":[{"name":"N\u00eemes University Hospital, N\u00eemes, France, and Institut Desbrest d\u2019Epidemiologie et de Sante Publique IDESP UMR UA11 INSERM, University Montpellier Montpellier France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore K.","family":"Kvien","sequence":"additional","affiliation":[{"name":"Diakonhjemmet Hospital Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[{"name":"Oregon Health &amp; Science University Portland Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tilt","sequence":"additional","affiliation":[{"name":"UCB Pharma Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Popova","sequence":"additional","affiliation":[{"name":"UCB Pharma Brussels Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris\u2010Saclay AP\u2010HP Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boulos","family":"Haraoui","sequence":"additional","affiliation":[{"name":"Department of Medicine Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al Montr\u00e9al Queb\u00e9c Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13101"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10524"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0770"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181039"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22926"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205675"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1315-z"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.J.00949"},{"key":"e_1_2_9_10_1","first-page":"653","article-title":"Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease\u2010modifying anti\u2010rheumatic drugs","volume":"32","author":"Emery P","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121288"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0029665112000092"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu045"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4113-3"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10529"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.089276"},{"key":"e_1_2_9_17_1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/annrheumdis-2012-eular.3031","article-title":"Effects of different steroid doses on adverse events and radiographic progression of certolizumab pegol\u2010treated rheumatoid arthritis patients","volume":"71","author":"Haraoui B","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151043"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2945-y"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq242"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes413"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150995"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209322"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000942"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00382"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.03.018"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2016.1240783"},{"key":"e_1_2_9_29_1","first-page":"Cd011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"12","author":"Sbidian E","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_30_1","first-page":"CD012183","article-title":"Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease\u2010modifying anti\u2010rheumatic drugs: a systematic review and network meta\u2010analysis","volume":"2016","author":"Singh JA","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.2217\/17460816.2.6.587"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31651-8"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1466-y"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054205"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21649"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"e_1_2_9_38_1","unstructured":"US Department of Health and Human Services National Institutes of Health.High blood cholesterol: what you need to know.2005. URL:https:\/\/www.nhlbi.nih.gov\/files\/docs\/public\/heart\/wyntk.pdf."},{"key":"e_1_2_9_39_1","unstructured":"World Health Organization.Factsheet: obesity and overweight.2020. URL:https:\/\/www.who.int\/en\/news\u2010room\/fact\u2010sheets\/detail\/obesity\u2010and\u2010overweight."},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203660"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01145-8"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0064-4"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.30134"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209270"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2014.00020"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12320"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135871"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2014.04.004"},{"key":"e_1_2_9_49_1","article-title":"The prevalence of autoimmune disorders in women: a narrative review","volume":"15","author":"Angum F","year":"2020","journal-title":"Cureus"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00081409"},{"issue":"1","key":"e_1_2_9_51_1","first-page":"27","article-title":"Infections in patients with diabetes mellitus: a review of pathogenesis","volume":"16","author":"Casqueiro J","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxs009"}],"container-title":["ACR Open Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/acr2.11259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr2.11259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T17:18:50Z","timestamp":1759425530000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr2.11259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/acr2.11259"],"URL":"https:\/\/doi.org\/10.1002\/acr2.11259","archive":["Portico"],"relation":{},"ISSN":["2578-5745","2578-5745"],"issn-type":[{"value":"2578-5745","type":"print"},{"value":"2578-5745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"2020-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}